• Vaccine Name: Bordetella pertussis BPZE vectored vaccine
• Target Pathogen: Bordetella pertussis
• Target Disease: Whooping Cough
• Vaccine Ontology ID: VO_0004608
• Type: Recombinant vector vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• Antigen: The pertussis toxin gene, which encodes a highly virulent toxin (Mielcarek et al., 2006).
• Vector:
  • Vector name:
  • VO vector ID: VO_0001037
• Immunization Route: intranasal immunization
• Virulence: The pertussis toxin itself if extremely virulent, but after thorough and careful attenuation, the virulence is basically gone (Mielcarek et al., 2006).
• Description: This is an intranasal vaccine because pathogenic B. pertussis colonizes the respiratory tract of humans. The vaccine itself has been shown to only need one inoculation in order to elicit protection, making it a good candidate to be a vaccine vector for other diseases (Mielcarek et al., 2006).

Mouse Response

• Vaccination Protocol: The mice were vaccinated with highly-attenuated B. pertussis in order to prepare for challenge with virulent wild-type B. pertussis (Mielcarek et al., 2006).
• Vaccine Immune Response Type: VO_0000287
• Challenge Protocol: After the mice had been inoculated with attenuated B. pertussis (which after a month had colonized the entire mouse respiratory tract) they were challenged with virulent wild-type B. pertussis (Mielcarek et al., 2006).
• Efficacy: A single intranasal inoculation of mice with the B. pertussis vaccine vector induced the same level of protection, if not higher, as two injections of the commercial acellular vaccine (Mielcarek et al., 2006) .
• Description: Inoculation with the B. pertussis vaccine vector shows protective immunity which rivals that of the vaccines currently on the market.